Denali Therapeutics Inc.
DNLI Nasdaq
SEC CIK 1714899
Follow Denali Therapeutics
Weekly email: filings, results
Revenue, last quarter
$17.8M
Net income
$70.1M
+155.3% vs same quarter last year
EPS, diluted
$0.37
+150% vs same quarter last year
Operating cash flow
−$117.4M
−9.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$512.5M |
| FY24 | $0 | −$422.8M |
| FY23 | $330.5M | −$145.2M |
| FY22 | $105.1M | −$326M |
| FY21 | $48.7M | −$290.6M |
| FY20 | $335.6M | $71.1M |
| FY19 | $26.3M | −$197.6M |
| FY18 | $129.1M | −$36.2M |
| FY17 | $0 | −$88.2M |
| FY16 | $0 | −$86.7M |
| FY15 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | −59.5% | −43.9% |
| FY22 | −324.3% | −310.3% |
| FY21 | −607.8% | −597.2% |
| FY20 | 18.7% | 21.2% |
| FY19 | −810% | −750.8% |
| FY18 | −35.9% | −28.1% |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$422.1M |
| FY24 | −$363.6M |
| FY23 | −$370.9M |
| FY22 | −$262.5M |
| FY21 | −$219.9M |
| FY20 | $413.1M |
| FY19 | −$169.5M |
| FY18 | $46.7M |
| FY17 | −$79.5M |
| FY16 | −$78M |
| FY15 | - |
- Denali Therapeutics
- Healthcare median
Show the numbers
| Year | Denali Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | −43.9% | −58% |
| FY22 | −310.3% | −80.4% |
| FY21 | −597.2% | −71.8% |
| FY20 | 21.2% | −62.2% |
| FY19 | −750.8% | −46.2% |
| FY18 | −28.1% | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |